discovery of glp-1 receptor assay: drug in the metabolic field A Brief History of GLP-1

The persistent difficulty in regulating food intake has contributed to the increasing acceptance of uncontrolled eating qualifying as an addiction disorder, similar to established models of drug abuse

it often depends upon a high index of suspicion engendered by the finding of failure to thrive and Fanconi syndrome

Wegovy (semaglutide 2.4 mg) is a GLP-1 receptor agonist licensed for chronic weight management in adults with obesity or overweight with weight-related comorbidities

Fernando and Wijayasinghe, 2021)

Val8-glucagon-like peptide-1 protects against Abeta1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats

Our findings suggest that GLP-1s could serve as an adjunctive therapy for HS patients, especially those with metabolic comorbidities, Neal Gupta, MD, a resident at SUNY Downstate Health Sciences University, told Healio